Time filter

Source Type

Petah Tikva, Israel

Tau N.,Davidoff Cancer Treatment Center | Lahav M.,Davidoff Cancer Treatment Center
Israel Medical Association Journal

Background: Diffuse large B cell lymphoma (DLBCL) is a hematologic malignancy characterized by an acute manifestation with a rapid deterioration of the patient's condition if no treatment is given during the early stages of the disease. MicroRNA molecules are known to be involved in the development of different malignancies. Specific microRNA signatures are known to be related to the prognosis of patients with some of these malignancies Objectives: To determine whether microRNA signature profiling can distinguish between DLBCL patients with a good prognosis and those with a bad prognosis Methods: Two groups were defined: good prognosis group (complete remission without relapse of the disease in 5 years) - 40 patients, and bad prognosis group (lack of complete remission or relapse of the disease within 9 months of diagnosis) - 43 patients. We extracted microRNA from the biopsies obtained during diagnosis and compared the microRNA profiles of the two groups by using Rosetta Genomics microRNA chips. Results: Our findings clearly show that combining hsa-miR- 342-3p with hsa-miR-17 produced the best sensitivity (79%) and specificity (73%) to predict the patient's prognosis, regardless of the disease stage or other clinical parameters. Conclusions: It may be possible to predict the prognosis of patients with DLBCL, and perhaps change the treatment of patients according to the genetics of the tumor. Source

Discover hidden collaborations